Arelis Madera, MD
Endocrinology, Diabetes & Metabolism · Port Charlotte, FLNPI 1487697272
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $1,304,072 of the $1,673,351 with a category attached, or 77.9%. 60 manufacturers reported payments, led by Lilly USA, LLC at 37.8% of the total. Among endocrinology, diabetes & metabolism clinicians in FL with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 3,131 payments — averaging $534.45 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Lilly USA, LLC$633K
- Novo Nordisk$374K
- Bayer$229K
- Dexcom, Inc.$148K
- Abbott$74K
- AstraZeneca$56K
- plus $160K from 54 others
What the payments were for
- Consulting fees$49,3083%
- Speaking & faculty fees$1,304,07278%
- Travel & lodging$267,31816%
- Food & beverage$52,3413%
- Education$3130%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- MOUNJARO$286,427
- TRULICITY$232,097
- Kerendia$227,100
- RYBELSUS$158,734
- Ozempic$152,579
- DEXCOM G7 GSS (161)$91,323
- FARXIGA$54,916
- DEXCOM G6 TRANSMITTER$39,763
- FreeStyle Libre Pro$33,872
- FREESTYLE LIBRE 3$33,438
- Tresiba$33,085
- DEXCOM STELO GLUCOSE BIOSENSOR$28,547
- SOLIQUA 100/33$25,994
- GVOKE PFS$22,502
- TOUJEO$21,228
- Repatha$14,154
- Tymlos$12,711
- TZIELD$11,505
- Synthroid$11,368
- DEXCOM CGM$10,137
How this compares
$1,673,351 in reported general payments places this provider in the 95th percentile of 586 endocrinology, diabetes & metabolism providers in Florida.
See all endocrinology, diabetes & metabolism providers in Florida →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 733 | $1,399,146 |
| MounjaroTirzepatide | 385 | $772,914 |
| Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/7 | 280 | $556,581 |
| TrulicityDulaglutide | 273 | $487,888 |
| Tresiba Flextouch U-200Insulin Degludec | 354 | $462,183 |
| KerendiaFinerenone | 287 | $397,983 |
| CreonLipase/Protease/Amylase | 49 | $382,262 |
| Humulin R U-500 KwikpenInsulin Regular, Human | 129 | $368,124 |
| FarxigaDapagliflozin Propanediol | 251 | $353,645 |
| JardianceEmpagliflozin | 235 | $326,563 |
| ZenpepLipase/Protease/Amylase | 35 | $316,788 |
| Tresiba Flextouch U-100Insulin Degludec | 362 | $284,075 |
| HetliozTasimelteon | 11 | $256,927 |
| ForteoTeriparatide | 55 | $248,375 |
| RybelsusSemaglutide | 103 | $215,265 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus, Fiasp, Novolog | $374,109 | $1,870,8121,023 claims |
| Lilly USA, LLCMounjaro, Trulicity, Forteo, Lyumjev, Humalog | $632,544 | $1,636,236820 claims |
| BayerKerendia | $229,334 | $397,983287 claims |
| AbbVieCreon | $18,371 | $382,26249 claims |
| AstraZenecaFarxiga | $56,031 | $353,645251 claims |
| Boehringer IngelheimJardiance | $77 | $326,563235 claims |
| Aimmune Therapeutics, Inc.Zenpep | $40 | $316,78835 claims |
| Vanda Pharmaceuticals Inc.Hetlioz | $178 | $256,92711 claims |
| Radius Health, Inc.Tymlos | $13,546 | $68,19826 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33 | $50,060 | $60,55849 claims |
| MerckJanuvia | $4,041 | $57,74038 claims |
| Johnson & JohnsonInvokana | $6,946 | $53,02332 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 586 endocrinology, diabetes & metabolism providers in Florida.
Other endocrinology, diabetes & metabolism in Port Charlotte
- Lenita HansonPort Charlotte$75K
- Jay SkylerMiami$2.2M
- Damon TantonOrlando$1.2M
- Gaston PonteMelbourne$906K
- Brian LakeLargo$888K
- David SuttonJacksonville$783K
- Mae Sheikh AliJacksonville$751K
- Richard PratleyOrlando$735K
- Lee MetchickDeland$728K
- Misha DenhamCoral Gables$673K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.